

# CERTIFICATE

Survey of 19 May 2023

You have fulfilled the requirements of the External Quality Assessment with the following analysis

## Anticonvulsants 03 (871):

Validity 12 months:

Lacosamide

(R) analysis is subject to the RiliBÄK

**Participant:**


42935

MUDr.,PhD. Tomas Salek  
Krajska nemocnice T.Bata, a.s.  
Department of Clinical Biochemistry &  
Pharmacology  
Havlickovo nabrezi 600  
76275 Zlin

Düsseldorf, 15 June 2023



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. med. Werner Steimer  
(Adviser)

# CERTIFICATE OF PARTICIPATION

Survey of 19 May 2023

You have participated in the External Quality Assessment with the following analysis

## Anticonvulsants 03 (871):

Lacosamide


(R) analysis is subject to the RiliBÄK

**Participant:**  
42935  
MUDr.,PhD. Tomas Salek  
Krajska nemocnice T.Bata, a.s.  
Department of Clinical Biochemistry &  
Pharmacology  
Havlickovo nabrezi 600  
76275 Zlin

Düsseldorf, 15 June 2023



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. med. Werner Steimer  
(Adviser)